Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Randomized, Partially Double-Blind, Placebo- and Active-Controlled, Four-period Crossover, Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

NCT06591845 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06591845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06591845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Randomized, Partially Double-Blind, Placebo- and Active-Controlled, Four-period Crossover, Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 25, 2024
Completion date
December 23, 2024
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers